quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:02:10·48d
INSIDERFiling
Iovance Biotherapeutics Inc. logo

Interim CEO & General Counsel Vogt Frederick G converted options into 62,493 shares and covered exercise/tax liability with 26,755 shares, increasing direct ownership by 7% to 529,538 units (SEC Form 4)

IOVA· Iovance Biotherapeutics Inc.
Health Care
Original source

Companies

  • IOVA
    Iovance Biotherapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 25UpdateCitizens$5.00
  • Jul 15UpdateGoldman$1.00
  • May 16UpdateUBS$2.00
  • May 12UpdateTruist-
  • May 9UpdateCitizens JMP-
  • Oct 24UpdateUBS$17.00

Related

  • PR6d
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  • SEC6d
    SEC Form PRE 14A filed by Iovance Biotherapeutics Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Iovance Biotherapeutics Inc.
  • PR34d
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  • SEC34d
    Iovance Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER43d
    SEC Form 4 filed by Chief Financial Officer Roche Corleen M.
  • INSIDER43d
    SEC Form 4 filed by Iovance Biotherapeutics Inc.
  • INSIDER43d
    SEC Form 4 filed by Iovance Biotherapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022